First‑Line Induction Therapy for Autoimmune Hepatitis

Corticosteroid Selection and Dosing

• Prednisolone is the preferred initial corticosteroid for adults, started at 0.5 mg/kg/day (up to 1 mg/kg/day in severe disease) as a single morning dose not exceeding 40 mg/day; higher initial doses do not improve biochemical response or mortality but increase adverse effects【1】.
• In children, prednisolone should be dosed at 1–2 mg/kg/day, capped at 40 mg/day【2】.
• Budesonide 9 mg/day is an alternative for non‑cirrhotic adults without liver failure when cosmetic side‑effects are a major concern, providing comparable biochemical response with fewer cosmetic adverse events【2】【1】【3】.
• Budesonide must never be used in patients with cirrhosis because reduced first‑pass metabolism leads to higher systemic exposure【1】【3】.

Steroid‑Sparing Agent Selection

Azathioprine

• Initiate azathioprine 2 weeks after starting corticosteroids (when bilirubin < 6 mg/dL) at 50 mg/day, then titrate to 1–2 mg/kg/day by week 4【4】【5】【2】.
• TPMT enzyme activity must be checked before azathioprine; homozygous TPMT deficiency is a contraindication, while heterozygous deficiency permits standard dosing with close monitoring【2】.
• Perform a complete blood count at 2 weeks and then monthly for the first 3 months, as azathioprine‑related cytopenia peaks within the first 6 weeks【4】【2】.

Mycophenolate Mofetil (MMF)

• MMF is an equally effective first‑line option; start at 1,000 mg/day together with corticosteroids and increase to 1,500–2,000 mg/day at week 2【4】【5】.
• MMF is teratogenic; both male and female patients must use two contraceptive methods, obtain negative pregnancy tests, and receive comprehensive counseling before initiation【4】【5】.
• Because MMF toxicity is rare, laboratory monitoring can be performed at 4 weeks rather than 2 weeks【4】.

Rationale for Combination Therapy

• Combining a corticosteroid with a steroid‑sparing agent is strongly preferred over corticosteroid monotherapy, as it reduces steroid‑related adverse effects and improves long‑term outcomes【5】【3】.

Corticosteroid Tapering Strategy

• Begin tapering prednisolone after documented biochemical improvement, reducing the dose by 5–10 mg every 1–2 weeks over 1–3 months to reach a maintenance dose of 5–10 mg/day (or budesonide to 6 mg/day)【4】【2】.
• Tapering should be guided by ALT and IgG levels measured at weeks 4, 12, and 24; rapid tapering may improve adherence but must only be done when response is confirmed【4】【5】.
• As corticosteroids are reduced, azathioprine can be escalated from 1 to 2 mg/kg/day with ongoing CBC monitoring【2】.

Situations Requiring Corticosteroid Monotherapy

• Decompensated cirrhosis, uncertain AIH diagnosis, anticipated short treatment duration (e.g., after withdrawal of a drug trigger), homozygous TPMT deficiency, concurrent allopurinol therapy, or recent/current malignancy warrant corticosteroid monotherapy without a steroid‑sparing agent【2】【1】【3】.

Monitoring During Treatment

Laboratory Surveillance

• Measure ALT and IgG at weeks 4, 12, and 24 to assess biochemical response【4】.
• CBC monitoring: at 2 weeks then monthly for 3 months in azathioprine‑treated patients; at 4 weeks in MMF‑treated patients【4】.
• After achieving complete biochemical response at 6 and 12 months, continue follow‑up every 3–6 months during maintenance therapy【4】.
• Check thyroid function (TSH, free T4, anti‑thyroid antibodies) every 6–12 months, as subclinical thyroid disorders are common【4】.

Non‑Invasive Fibrosis Assessment

• Perform regular transient elastography to monitor liver fibrosis progression【4】.

Bone Health Management

• Provide adequate calcium intake and vitamin D supplementation to all patients on long‑term corticosteroids【4】【2】.
• Obtain a baseline DEXA scan and repeat during follow‑up; AIH patients have an age‑related fracture risk of ≈ 17.5 per 1,000 person‑years【5】.
• Calculate FRAX scores for adults starting steroids; those at high fracture risk should commence bisphosphonates promptly, pending DEXA confirmation【2】.

Ophthalmologic Surveillance

• Conduct a baseline ophthalmologic examination with intra‑ocular pressure measurement and schedule periodic follow‑up; about two‑thirds of patients develop asymptomatic raised intra‑ocular pressure【5】.

Contraindications and Safety Alerts

• Budesonide must never be used in cirrhotic patients due to shunting and increased systemic exposure【1】【3】.
• Intravenous methylprednisolone should be avoided because of a 6–8 % incidence of hepatotoxicity (≈ 2 % severe, including fatalities)【1】【3】.
• Do not start azathioprine when bilirubin ≥ 6 mg/dL; wait until bilirubin improves【5】.
• Proactively manage treatment‑related adverse events rather than waiting for complications to arise【4】.
• Document MMF contraception counseling for both sexes before initiation【4】【5】.
• Monitor adherence closely, especially in children, adolescents, and young adults, as non‑adherence markedly worsens outcomes【5】.

Pediatric Autoimmune Hepatitis – Evidence‑Based Treatment Recommendations

Initial First‑Line Therapy

• Children with autoimmune hepatitis should receive prednisolone at 1–2 mg/kg/day (maximum 40 mg/day) together with azathioprine; azathioprine is introduced ≈ 2 weeks after starting steroids once serum bilirubin is below 6 mg/dL. 6

Corticosteroid Choice and Dosing in Children

• Prednisolone is initiated as a single morning dose of 1–2 mg/kg/day, capped at 40 mg/day. 6
• Budesonide must not be used in children who have cirrhosis because reduced first‑pass metabolism leads to higher systemic exposure. 6
• In non‑cirrhotic children without acute severe hepatitis, budesonide 9 mg/day may be considered when cosmetic steroid side effects are a major concern. 6

Mycophenolate Mofetil as an Alternative First‑Line Agent

• Mycophenolate mofetil (MMF) started at 1,000 mg/day and escalated to 1,500–2,000 mg/day by week 2 provides efficacy comparable to azathioprine. 6

Management of Acute Severe Autoimmune Hepatitis or Acute Liver Failure

• For acute severe AIH, prednisolone monotherapy is recommended at 0.5–1 mg/kg/day in adults and up to 2 mg/kg/day in children. 6
• Budesonide must not be used in acute severe AIH or in patients with cirrhosis. 6
• Glucocorticoid therapy yields clinical improvement in 20–100 % of acute severe AIH cases and does not increase the risk of sepsis. 6
• In acute liver failure with a Model for End‑Stage Liver Disease (MELD) score > 40, glucocorticoids have not demonstrated a survival benefit. 6

Calcineurin Inhibitor Options for Refractory Disease

• Tacrolimus, with or without prednisolone, achieves 1‑year remission rates comparable to standard therapy, although the early response (at 3 and 6 months) is slower; it is not recommended as a first‑line option. 6
• Cyclosporine can induce remission in children when trough levels are maintained at 150–200 ng/mL initially and tapered to 50–70 ng/mL after one year. 6
• Current evidence is insufficient to endorse calcineurin inhibitors (tacrolimus or cyclosporine) as front‑line agents for pediatric AIH. 6

Initiation and Management of Immunosuppressive Therapy in Autoimmune Hepatitis with Cirrhosis

Indications for Treatment

• Initiating combined corticosteroid + azathioprine therapy in patients with autoimmune hepatitis and cirrhosis improves survival and prevents disease progression, even when cirrhosis is already established. 7, 8
• Age ≥ 60 years and the presence of cirrhosis are not contraindications to treatment; they are indications for therapy rather than reasons to withhold it. 7, 8

Initial Corticosteroid Regimen

• Begin prednisolone at 0.5 mg/kg/day (maximum 40 mg/day) as a single morning dose. 8
• Doses above 40 mg/day do not enhance biochemical response or mortality but markedly increase adverse events such as fractures and cataracts. 8
• Taper prednisolone by 5–10 mg every 2 weeks over a 3‑month period as aminotransferases decline, aiming for a maintenance dose of 5–10 mg/day. 8

Azathioprine Co‑Therapy (Timing Not Cited)

(No specific citation provided for initiation timing; omitted per instructions.)

Monitoring and Assessment

• Measure ALT and IgG at weeks 4, 12, and 24; complete biochemical remission is defined by normalization of both aminotransferases and IgG. 7
• Conduct surveillance for hepatocellular carcinoma and portal‑hypertension complications according to generic cirrhosis guidelines; the annual HCC incidence in AIH‑related cirrhosis is 0.5–1 %. 9
• Perform non‑invasive fibrosis assessment (transient elastography) every 2–3 years. 9

Contraindicated Therapies

• Budesonide is absolutely contraindicated in cirrhotic patients because intra‑hepatic shunting reduces first‑pass metabolism, increasing systemic exposure and the risk of portal‑vein thrombosis. 7, 8
• Intravenous methylprednisolone should be avoided; it is associated with a 6–8 % incidence of hepatotoxicity (≈ 2 % severe, including fatalities). 8

Long‑Term Management and Treatment Cessation

• Most patients require long‑term, often lifelong, immunosuppressive therapy, irrespective of age or cirrhotic status. 7
• Discontinuation of therapy should be considered only after maintaining a stable complete biochemical response on low‑dose monotherapy for ≥ 2 years in carefully selected patients. 7
• Relapse rates after drug withdrawal range from 50 % to 86 %; after a first relapse, further attempts at cessation are not recommended. 7